The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Anupam Rama - JPMorgan Chase & Co. - Analyst
: Thanks, Bo. So i'll just remind folks, like I have always said, there are three ways to ask your question, right. There's raise your hand the old-school
method of call on you, if you have access to the question portal, you can submit it and it'll show upon this ipad and I'm happy to ask on your behalf.
I guess there's an intermediate strategy where you can e-mail me and I'll do this same thing. So but I will start if that's cool.
Question: Anupam Rama - JPMorgan Chase & Co. - Analyst
: So on SGT-003 , you talked about, you know, enrolling that first set of patients. Have you identified the shape of patients? Have you identified
mapped them to a site?
Question: Anupam Rama - JPMorgan Chase & Co. - Analyst
: Can you comment a little bit about the age of the patients that are going to be enrolling in the first couple.
Question: Anupam Rama - JPMorgan Chase & Co. - Analyst
: How are you thinking about scenarios around the Elavatus label expansion and how that will either impact your near term or long term development
of SGT-003, whether it's from a clinical or enrollment perspective?
Question: Anupam Rama - JPMorgan Chase & Co. - Analyst
: Questions from the audience.
Unidentified Participant
Hello? Yeah, thank you for the nice talk. So you mentioned that the use of the dual plasma system for further protection. So 90% full ratio is really
high. I mean, that's really high. So can you disclose your productivity? We know that it is tropo is a pretty big. So you really we have very low yields.
So do you have a data for like the productivity.
Question: Anupam Rama - JPMorgan Chase & Co. - Analyst
: Additional questions. Question Malcolm.
Unidentified_1
So when we look at day four expression 003 better across the board, but I know sort of a little bit of a lag on when it comes to cardiac is that because
cardiac expression takes longer? Or is 003 just more targeted towards the large muscle groups?
Question: Anupam Rama - JPMorgan Chase & Co. - Analyst
: We've got a question in the portal.
Unidentified_2
How do you think about the potential to partner aspects of your platform or other cardiac gene therapy programs to accelerate time lines to clinic
for your pipeline.
Question: Anupam Rama - JPMorgan Chase & Co. - Analyst
: Questions from the audience.
Unidentified_3
Is it fair to say that you kind of prioritize CPVT now over, say Friedreich's ataxia? Yeah is there because Frederick Taxi was kind of like the second
adapter DMD scale looking at the target. Our target obviously is strategic switch, the yes, as well.
Question: Anupam Rama - JPMorgan Chase & Co. - Analyst
: Any final questios ?
Unidentified_4
Thank you .
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
JANUARY 11, 2024 / 5:45PM, SLDB.OQ - Solid Biosciences Inc at JPMorgan Healthcare Conference
Question: Anupam Rama - JPMorgan Chase & Co. - Analyst
: Thanks, everyone.
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
JANUARY 11, 2024 / 5:45PM, SLDB.OQ - Solid Biosciences Inc at JPMorgan Healthcare Conference
| 
